In vitro RNPA1000 antimicrobial properties.

aOrganism and relevant antibiotic resistance phenotype (in parentheses); methicillin resistant S. aureus (MRSA); vancomycin intermediate S. aureus (VISA); vancomycin resistant S. aureus (VRSA); multidrug resistant S. pneumoniae (MDR); vancomycin resistant E. faecium (VRE).bWith the exception of S. aureus and S. bovis, all strains were clinical blood isolates; USA-types (U.S. MRSA lineages) were obtained from the Centers for Disease Control and Prevention; S. aureus strain UAMS-1 is a clinical osteomyelitis isolate; isolates NRS1, NRS3, VRS1 and VRS10 were obtained through the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA); S. bovis strain ATCC49147 was obtained from the American Type Culture Collection (ATCC).cMinimal inhibitory concentration (MIC) was determined following the Clinical and Laboratory Standards Institute (CLSI) guidelines for antimicrobial susceptibility testing. Each S. aureus strain was tested 5 times; other organisms were tested in duplicate. S. aureus isolates were subsequently more accurately measured as described within Materials and Methods.